Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407069 · ClinicalTrials.gov registry record
Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 286
- Enrollment target
NCT00407069: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00407069 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 286 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00407069 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 286 participants
- Enrollment target
Study Summary
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP) expression. The purpose of this study is to compare smallpox virus replication and the number of AMPs and other antiviral molecules in people with AD, as compared to those seen in people with psoriasis or asthma, or healthy individuals.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-02 |
What the finished NCT00407069 record still lists
NCT00407069 is an observational study that tracks outcomes without assigning an intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00407069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00407069 about?
NCT00407069 is a clinical study titled "Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus". Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP) expression. The purpose of this study is to compare smallpox virus replicati...
What is the current status of trial NCT00407069?
This trial is currently completed. The enrollment target is 286 participants. The study started on 2005-06. Estimated completion is 2010-02.
Who is sponsoring clinical trial NCT00407069?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia